{{Drugbox
| verifiedrevid = 462252859
| IUPAC_name = (''RS'')-1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
| image = Mitotane.svg
| width = 200
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename = Lysodren
| Drugs.com = {{drugs.com|monograph|mitotane}}
| MedlinePlus = a608050
| licence_US = MITOTANE
| pregnancy_category = C
| legal_status = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 40%
| protein_bound = 6%
| metabolism = 
| elimination_half-life = 18 to 159 days
<!--Identifiers-->
| IUPHAR_ligand = 6957
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 53-19-0
| ATC_prefix = L01
| ATC_suffix = XX23
| ATC_supplemental = 
| PubChem = 4211
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00648
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4066
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 78E4J5IB5J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00420
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1670
<!--Chemical data-->
| C=14 | H=10 | Cl=4
| molecular_weight = 320.04 g/mol
| smiles = Clc1ccccc1C(c2ccc(Cl)cc2)C(Cl)Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JWBOIMRXGHLCPP-UHFFFAOYSA-N
| synonyms = 1,1-(Dichlorodiphenyl)-2,2-dichloroethane; o,p'-DDD
| melting_point = 76
| melting_high = 78
}}

'''Mitotane''', sold under the brand name '''Lysodren''', is a [[steroidogenesis inhibitor]] and [[cytostatic]] [[antineoplastic]] medication which is used in the treatment of [[adrenocortical carcinoma]] and [[Cushing's syndrome]].<ref name="JamesonGroot2010">{{cite book|author1=J. Larry Jameson|author2=Leslie J. De Groot|title=Endocrinology - E-Book: Adult and Pediatric|url=https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA1888|date=18 May 2010|publisher=Elsevier Health Sciences|isbn=1-4557-1126-8|pages=1888–}}</ref><ref name="pmid15898346">{{cite journal |vauthors=Hahner S, Fassnacht M |title=Mitotane for adrenocortical carcinoma treatment |journal=Current opinion in investigational drugs (London, England : 2000) |volume=6 |issue=4 |pages=386–94 |date=April 2005 |pmid=15898346 |doi= |url=}}</ref><ref name="Bronstein2010">{{cite book|author=Marcello D. Bronstein|title=Cushing's Syndrome: Pathophysiology, Diagnosis and Treatment|url=https://books.google.com/books?id=5_ulQAM9OZYC&pg=PA156|date=1 October 2010|publisher=Springer Science & Business Media|isbn=978-1-60327-449-4|pages=156–}}</ref><ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA382|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=382–}}</ref> It is a [[chemical derivative|derivative]] of {{abbrlink|p,p'-DDT|dichlorodiphenyltrichloroethane}} and an [[isomer]] of {{abbrlink|p,p'-DDD|dichlorodiphenyldichloroethane}}, and is also known as '''1,1-(dichlorodiphenyl)-2,2-dichloroethane''' ('''o,p'-DDD''').<ref name="PubChem">[https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4211 Information from PubChem]</ref>

==Medical uses==
Mitotane has been produced by [[Bristol Myers Squibb]] SpA but it is marketed as an [[orphan drug]] for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone.<ref>{{cite journal|journal=N Engl J Med. | year = 2007 | volume = 356 | issue = 23 | pages = 2372–2380 | title=Adjuvant mitotane treatment for adrenocortical carcinoma|vauthors=Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A|doi=10.1056/NEJMoa063360|pmid=17554118}}</ref> The drug is also sometimes used in the treatment of Cushing's syndrome.<ref name="Bronstein2010" />

==Side effects==
The use of mitotane is unfortunately limited by [[side effect]]s,<ref name="HarrisBouloux2014" /> which, as reported by Schteinberg et al., include [[anorexia (symptom)|anorexia]] and [[nausea]] (88%), [[diarrhea]] (38%), [[vomiting]]  (23%), decreased [[memory]] and ability to concentrate (50%), [[rash]] (23%), [[gynecomastia]] (50%), [[arthralgia]] (19%), and [[leukopenia]] (7%).<ref>{{cite journal|vauthors=Schteinberg DE, Motazedi A, NoonanRA, Thompson NW|title=Treatment of Adrenal Carcinomas|journal=Arch.Surg. | year = 1982 | volume = 117 | pages = 1142–1149}}</ref>

==Pharmacology==
Mitotane is an inhibitor of the [[adrenal cortex]]. It acts as an [[enzyme inhibitor|inhibitor]] of [[cholesterol side-chain cleavage enzyme]] (P450scc, CYP11A1), and also of [[11β-hydroxylase]] (CYP11B1), [[18-hydroxylase]] (aldosterone synthase, CYP11B2), and [[3β-hydroxysteroid dehydrogenase]] (3β-HSD) to a lesser extent.<ref name="JamesonGroot2010" /><ref name="HarrisBouloux2014">{{cite book|author1=Philip E. Harris|author2=Pierre-Marc G. Bouloux|title=Endocrinology in Clinical Practice, Second Edition|url=https://books.google.com/books?id=tZE-AwAAQBAJ&pg=PA216|date=24 March 2014|publisher=CRC Press|isbn=978-1-84184-951-5|pages=216–}}</ref> In addition, mitotane has direct and selective [[cytotoxic]] effects on the adrenal cortex, via an unknown mechanism, and thereby induces permanent [[Adrenal insufficiency|adrenal atrophy]] similarly to DDD.<ref name="MPHMD2011">{{cite book|author1=Eudocia Quant Lee, MD, MPH|author2=David Schiff, MD|author3=Patrick Y. Wen, MD|title=Neurologic Complications of Cancer Therapy|url=https://books.google.com/books?id=52qyu5XPqM4C&pg=PA179|date=28 September 2011|publisher=Demos Medical Publishing|isbn=978-1-61705-019-0|pages=179–}}</ref><ref name="Kannan2012">{{cite book|author=C.R. Kannan|title=The Adrenal Gland|url=https://books.google.com/books?id=WqXSBwAAQBAJ&pg=PA160|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-1001-3|pages=160–}}</ref>

==History==
Mitotane was introduced in 1960 for the treatment of adrenocortical carcinoma.<ref name="Bronstein2010" />

==Society and culture==
''Mitotane'' is the [[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]], and [[Japanese Accepted Name|JAN]] of mitotane.<ref name="Elks2014" /><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA697|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=697–}}</ref>

==Veterinary use==
Mitotane is also used to treat [[Cushing's disease]] ([[pituitary]]-dependent [[Cushing's syndrome]]) in [[dog]]s. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.<ref>[http://www.michvma.org/documents/MVC%20Proceedings/Nichols2.pdf Canine Cushing’s Syndrome: Diagnosis and Treatment]</ref>

==See also==
* [[Aminoglutethimide]]
* [[Amphenone B]]
* [[Metyrapone]]

==References==
{{Reflist|2}}

==External links==
* {{cite journal | url = http://www.springerlink.com/content/wqjmv74186x57wx1 | author1 = V. P. Komissarenko | author2 = I. S. Chelnakova | author3 = A. S. Mikosha | title = Effect of o,p-dichlorodiphenyldichloroethane and perthane in vitro on glutathione reductase activity in the adrenals of dogs and guinea pigs | doi = 10.1007/BF00800110 | year = 1978 | journal = Bulletin of Experimental Biology and Medicine | volume = 85 | issue = 2 | pages = 152–154}}
* Government of Canada: ''[http://www.chemicalsubstanceschimiques.gc.ca/challenge-defi/summary-sommaire/batch-lot-12/53-19-0-eng.php Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl&#93;- (Mitotane)]''
* Environment Canada & Health Canada: ''[http://www.ec.gc.ca/ese-ees/434E69F1-1490-4CD3-A0BB-4A15CA8D0313/RM%20Scope_B12%20-%2053-19-0_EN.pdf RISK MANAGEMENT SCOPE for Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl&#93;- (Mitotane)]'', 2013


{{Chemotherapeutic agents}}
{{Glucocorticoids and antiglucocorticoids}}

[[Category:11β-Hydroxylase inhibitors]]
[[Category:Antiglucocorticoids]]
[[Category:Antineoplastic drugs]]
[[Category:Cholesterol side-chain cleavage enzyme inhibitors]]
[[Category:Organochlorides]]
[[Category:Chloroarenes]]
[[Category:Orphan drugs]]